135 related articles for article (PubMed ID: 37789147)
1. Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans.
Hofmann J; Bartůněk A; Hauser T; Sedmak G; Beránek J; Ryšánek P; Šíma M; Slanař O
Leukemia; 2023 Dec; 37(12):2486-2492. PubMed ID: 37789147
[TBL] [Abstract][Full Text] [Related]
2. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Larfors G; Andersson P; Jesson G; Liljebris C; Brisander M; Lennernäs H; Stenke L
Eur J Haematol; 2023 Oct; 111(4):644-654. PubMed ID: 37503797
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers.
Hasan A; Abul Kalam Azad M; Ullah MA; Mahbub Latif AH; Hasnat A
Int J Clin Pharmacol Ther; 2009 Mar; 47(3):215-21. PubMed ID: 19281731
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers.
Poo JL; Galán JF; Rosete A; de Lago A; Oliva I; González-de la Parra M; Jiménez P; Burke-Fraga V; Namur S
Clin Ther; 2008 Apr; 30(4):693-9. PubMed ID: 18498918
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
Vaidhyanathan S; Wang X; Crison J; Varia S; Gao JZH; Saxena A; Good D
J Pharm Sci; 2019 Jan; 108(1):741-749. PubMed ID: 30439460
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption.
Estevez-Carrizo FE; Parrillo S; Cedres M; Estevez-Parrillo FT; Rodriguez P
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):621-7. PubMed ID: 20860916
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers.
Joti JJ; Nahar K; Hasan A; Azad MA; Ullah MA; Islam SM; Hasnat A
Arzneimittelforschung; 2009; 59(4):171-5. PubMed ID: 19517893
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
11. Effect of Omeprazole Administration on the Pharmacokinetics of Oral Extended-Release Nifedipine in Healthy Subjects.
Zhao L; Sun D; Tan ML; Xu M; Kinjo M; Feng K; Wang H; Lionberger R
Clin Pharmacol Ther; 2023 Nov; 114(5):1134-1141. PubMed ID: 37669218
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Hwang KG; Kim YS; Shaw LM; Lee YS; Kang JS
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):23-9. PubMed ID: 19203529
[TBL] [Abstract][Full Text] [Related]
14. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb
Knaub K; Sartorius T; Dharsono T; Wacker R; Wilhelm M; Schön C
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426272
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform.
Lennernäs H; Brisander M; Liljebris C; Jesson G; Andersson P
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38808617
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
[TBL] [Abstract][Full Text] [Related]
17. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
18. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
19. A randomized, crossover study to determine bioequivalence of two brands of dexibuprofen 400 mg tablets in healthy Asian adult male subjects of Indian origin.
Menon S; Kadam N; Patil G; Mhatre P
Int J Clin Pharmacol Ther; 2008 Jan; 46(1):48-54. PubMed ID: 18218298
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
Francke K; Chattopadhyay N; Klein S; Rottmann A; Krickau D; van de Wetering J; Friedrich C
Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):75-87. PubMed ID: 36469250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
